Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer

S. Blagden; A. Hamilton; Linda Mileshkin; M. Hall; T. Meniawy; S. Wong; S. Anandra; M. Buck; D. McAleer; B. A. Reedy; R. B. Noble; D. A. Smith; S. R. Morris; H. Gabra

doi:10.1016/S0959-8049(14)70129-7

Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer

S. Blagden, A. Hamilton, Linda Mileshkin, M. Hall, T. Meniawy, S. Wong, S. Anandra, M. Buck, D. McAleer, B. A. Reedy, R. B. Noble, D. A. Smith, S. R. Morris, H. Gabra

UWA Medical School

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

5 Citations (Web of Science)

Original language	English
Pages (from-to)	7-7
Number of pages	1
Journal	European Journal of Cancer
Volume	50
DOIs	https://doi.org/10.1016/S0959-8049(14)70129-7
Publication status	Published - Nov 2014
Event	26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Barcelona, Spain Duration: 18 Nov 2014 → 21 Nov 2014

Access to Document

10.1016/S0959-8049(14)70129-7

Cite this

Blagden, S., Hamilton, A., Mileshkin, L., Hall, M., Meniawy, T., Wong, S., Anandra, S., Buck, M., McAleer, D., Reedy, B. A., Noble, R. B., Smith, D. A., Morris, S. R., & Gabra, H. (2014). Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer. European Journal of Cancer, 50, 7-7. https://doi.org/10.1016/S0959-8049(14)70129-7

Blagden, S. ; Hamilton, A. ; Mileshkin, Linda ; Hall, M. ; Meniawy, T. ; Wong, S. ; Anandra, S. ; Buck, M. ; McAleer, D. ; Reedy, B. A. ; Noble, R. B. ; Smith, D. A. ; Morris, S. R. ; Gabra, H. / Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer. In: European Journal of Cancer. 2014 ; Vol. 50. pp. 7-7.

@article{2764f951d4b1478c862ed263b682acdb,

title = "Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer",

author = "S. Blagden and A. Hamilton and Linda Mileshkin and M. Hall and T. Meniawy and S. Wong and S. Anandra and M. Buck and D. McAleer and Reedy, {B. A.} and Noble, {R. B.} and Smith, {D. A.} and Morris, {S. R.} and H. Gabra",

year = "2014",

month = nov,

doi = "10.1016/S0959-8049(14)70129-7",

language = "English",

volume = "50",

pages = "7--7",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier",

note = "26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics ; Conference date: 18-11-2014 Through 21-11-2014",

}

Blagden, S, Hamilton, A, Mileshkin, L, Hall, M, Meniawy, T, Wong, S, Anandra, S, Buck, M, McAleer, D, Reedy, BA, Noble, RB, Smith, DA, Morris, SR & Gabra, H 2014, 'Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer', European Journal of Cancer, vol. 50, pp. 7-7. https://doi.org/10.1016/S0959-8049(14)70129-7

Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer. / Blagden, S.; Hamilton, A.; Mileshkin, Linda; Hall, M.; Meniawy, T.; Wong, S.; Anandra, S.; Buck, M.; McAleer, D.; Reedy, B. A.; Noble, R. B.; Smith, D. A.; Morris, S. R.; Gabra, H.

In: European Journal of Cancer, Vol. 50, 11.2014, p. 7-7.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer

AU - Blagden, S.

AU - Hamilton, A.

AU - Mileshkin, Linda

AU - Hall, M.

AU - Meniawy, T.

AU - Wong, S.

AU - Anandra, S.

AU - Buck, M.

AU - McAleer, D.

AU - Reedy, B. A.

AU - Noble, R. B.

AU - Smith, D. A.

AU - Morris, S. R.

AU - Gabra, H.

PY - 2014/11

Y1 - 2014/11

U2 - 10.1016/S0959-8049(14)70129-7

DO - 10.1016/S0959-8049(14)70129-7

M3 - Abstract/Meeting Abstract

VL - 50

SP - 7

EP - 7

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

T2 - 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Y2 - 18 November 2014 through 21 November 2014

ER -